4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline
• 英文别名: 2-methyl-4-pentan-3-yloxy-8-(2,4,6-trimethylphenyl)quinoline
• 化学式: C₂₄H₂₉NO
• 分子量: 347.5
• InChiKey: SQVZUGHPSMFDBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-戊醇 、 4-chloro-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline 以 四氢呋喃 、 二甲基亚砜 为溶剂， 生成 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline
  参考文献：
  名称：

  Substituted6,6-hetero-bicyclicderivatives

  摘要：

  该发明涉及公式1中的化合物，其中A、B、D、E、K、G、R3和R5如规范中定义的那样，以及这些化合物的药用盐。

  公开号：

  US20030114671A1

文献信息

• Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm
  申请人：Pfizer Products Inc.

  公开号：EP1082960A2

  公开（公告）日：2001-03-14

  A corticotropin releasing factor (CRF) antagonist is administered to treat a condition selected from the group consisting of: c)disorders that can be treated by altering circadian rhythm; and d)depression, further wherein a second compound for treating depression is administered, the second compound for treating depression having an onset of action that is delayed with respect to that of the CRF antagonist.

  一种促肾上腺皮质激素释放因子（CRF）拮抗剂用于治疗选自以下组别的疾病： c)可通过改变昼夜节律来治疗的疾病；以及 d)抑郁症，其中还施用了治疗抑郁症的第二种化合物，治疗抑郁症的第二种化合物的起效时间比CRF拮抗剂的起效时间延迟。
• Use of corticotropin releasing factor antagonists for treating syndrome X
  申请人：Pfizer Products Inc.

  公开号：EP1097709A2

  公开（公告）日：2001-05-09

  The present invention relates to compositions and methods of achieving a thereapeutic effect including, the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.

  本发明涉及单独使用促肾上腺皮质激素释放因子（CRF）拮抗剂或与糖皮质激素受体拮抗剂一起使用以达到治疗或预防动物（最好是哺乳动物，包括人类或伴侣动物）X综合征的效果的组合物和方法。
• Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
  申请人：Pfizer Products Inc.

  公开号：EP1149583A2

  公开（公告）日：2001-10-31

  This invention is directed to pharmaceutical compositions comprising corticotropin releasing factor antagonist and growth hormone or growth hormone secretagogues, prodrugs thereof, or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to the use of such compositions in the treatment or prevention of osteoporosis and heart-related diseases (including congestive heart failure) in mammals, particularly humans.

  本发明涉及包含促肾上腺皮质激素释放因子拮抗剂和生长激素或生长激素促泌剂、其原药或所述化合物或所述原药的药学上可接受的盐的药物组合物。本发明还用于治疗或预防哺乳动物，特别是人类的骨质疏松症和心脏相关疾病（包括充血性心力衰竭）。
• Compound [2-(4-chloro-2,6-dimethyl-phenoxy)- 3,6-dimethyl-pyridin-4-yl]- (1-ethyl-propyl)- amine and use as CRF antagonist
  申请人：Pfizer Products Inc.

  公开号：EP1449532A1

  公开（公告）日：2004-08-25

  The compound [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine.

  化合物[2-(4-氯-2,6-二甲基-苯氧基)-3,6-二甲基吡啶-4-基]-(1-乙基丙基)-胺。
• Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
  申请人：——

  公开号：US20010041673A1

  公开（公告）日：2001-11-15

  This invention is directed to pharmaceutical compositions comprising corticotropin releasing factor antagonist and growth hormone or growth hormone secretagogues, prodrugs thereof, or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to methods of treating heart related diseases (including congestive heart failure) in mammals, and particularly in humans.

  本发明涉及包含促肾上腺皮质激素释放因子拮抗剂和生长激素或生长激素促泌剂、其原药或所述化合物或所述原药的药学上可接受的盐的药物组合物。本发明还涉及治疗哺乳动物，特别是人类心脏相关疾病（包括充血性心力衰竭）的方法。